Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2850398

O=C(O)C(F)(F)F.O=C(O)CCc1cnc2ccccc2c1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHOA P61586 1/20 0.48
MGAM O43451 1/20 0.48
RAB9A P51151 1/20 0.46
CFTR P13569 1/20 0.45
KEAP1 Q14145 1/20 0.45
TRPM5 Q9NZQ8 1/20 0.44
FFAR1 O14842 4/20 0.44
AKR1B1 P15121 1/20 0.44
DHODH Q02127 1/20 0.44
P4HTM Q9NXG6 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HDAC9 Q9UKV0 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2846347 0.93 MGAM (0.54) RHOAMGAMRAB9ACFTRKEAP1
Hydrochloric Acid SCHEMBL3867467 0.91 MGAM (0.53) RHOAMGAMRAB9ACFTRKEAP1
SCHEMBL5199025 0.84 CYP1A2 (0.60) RHOAMGAMRAB9ACFTRFFAR1
SCHEMBL5197022 0.83 CYP1A2 (0.55) MGAMRAB9ACFTRHDAC3HDAC4
SCHEMBL7832253 0.82 MAPT (0.57) MGAMCFTRHDAC3HDAC4HDAC1
SCHEMBL7821089 0.82 MAPT (0.57) MGAMCFTRHDAC3HDAC4HDAC1
SCHEMBL2850402 0.82 TRPM5 (0.44) MGAMRAB9ACFTRTRPM5DHODH
SCHEMBL530807 0.80 TRPM5 (0.50) MGAMRAB9ACFTRTRPM5DHODH
Trifluoroacetic Acid SCHEMBL27484822 0.78 CYP1A2 (0.69) KEAP1FFAR1HDAC1HDAC8FFAR4
SCHEMBL29750532 0.77 MGAM (0.57) MGAMRAB9ACFTRAKR1B1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152670-B1 BRIDGED SIX-MEMBERED RING COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2013-12-25 EP disclosed
US-8202885-B2 Bridged six-membered ring compounds ACTELION PHARMACEUTICALS LTD. (CH) 2012-06-19 US disclosed
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS IDORSIA PHARMACEUTICALS LTD (CH) 2010-05-27 US disclosed
EP-2152670-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2010-02-17 EP disclosed
WO-2008132679-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130545-A1 BRIDGED SIX-MEMBERED RING COMPOUNDS CACNA1E, CACNA1B, CACNA1A RHOA 1169/4885MGAM 4772/4885RAB9A 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.